155 results
8-K
EX-99.1
WVE
Wave Life Sciences Ltd.
6 Mar 24
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:39am
and potential benefits of our collaborations; the potential achievement of milestones under our collaborations and receipt of cash payments therefor … and their therapeutic potential; the anticipated benefits of our therapeutic candidates and pipeline compared to our competitors; our ability to design
424B5
WVE
Wave Life Sciences Ltd.
8 Dec 23
Prospectus supplement for primary offering
6:06am
and maintain regulatory approvals for any of our product candidates;
the potential benefits that may be derived from any of our product candidates;
our … ;
the timing of, and our ability to, obtain and maintain regulatory approvals for any of our product candidates;
the potential benefits that may
8-K
EX-1.1
wfe8ka6r149 1ol8dct3
7 Dec 23
Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
9:26pm
424B5
7r7ap873
6 Dec 23
Prospectus supplement for primary offering
4:13pm
8-K
EX-99.1
84qau0h8
9 Nov 23
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
7:39am
8-K
EX-99.1
sg4u lpsh6046d6a
28 Sep 23
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
4:38pm
8-K
EX-10.1
slofsp7s6xgalbzt3y51
7 Aug 23
Departure of Directors or Certain Officers
5:01pm
8-K
EX-99.1
cqzdpoiv6
3 Aug 23
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
7:37am
8-K
EX-99.1
fpfeayf
23 May 23
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated
7:48am
8-K
EX-99.1
5k82037yn6kz3pnltm
3 May 23
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
7:43am
8-K/A
EX-99.1
2fae tgnz
19 Dec 22
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
10:17am